ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±ÒÁ²©Ñô£©»ù¿×¿ÏÑÅÈÈ£¨CHIKF£©ÊÇÓÉ»ù¿×¿ÏÑŲ¡¶¾£¨CHIKV£©ÒýÆð£¬£¬¾ÒÁÎÃÈö²¥£¬£¬ÒÔ·¢ÈÈ¡¢Æ¤Õî¼°ÊàŦÌÛʹΪÖ÷ÒªÌØÕ÷µÄ¼±ÐÔѬȾ²¡¡£¡£CHIKVͨ³£ÔÚ·ÇÈËÀàÁ鳤ÀදÎï¡¢²¸È鶯ÎïËÞÖ÷ºÍÎóæÖ®¼äÒÔÇúÏßʽѻ·Èö²¥¡£¡£1952ÄêÊ×´ÎÔÚ̹ɣÄáÑÇ֤ʵÁË»ù¿×¿ÏÑÅÈÈÊ¢ÐУ¬£¬1956ÄêÊèÉ¢µ½²¡¶¾¡£¡£2005£2007Äê±¾²¡ÔÚÓ¡¶ÈÑóµºÓì¡¢Ó¡¶ÈºÍ¶«ÄÏÑǵØÇøÆÕ±éÊ¢ÐУ¬£¬µ¼ÖÂÊý°ÙÍòÈË»¼²¡¡£¡£ÏÖÔÚ£¬£¬ÔÚÑÇÖÞ¡¢·ÇÖÞ¡¢Å·ÖÞÒÔ¼°ÃÀÖ޵Ľü60¸ö¹ú¼ÒÒѾȷÈÏÓлù¿×¿ÏÑŲ¡Àý±¬·¢¡£¡£
¹ØÓÚCHIKVµÄ·ÀÖΣ¬£¬ÏÖÔÚûÓпÉÒÔʹÓõÄÒßÃçÉÏÊУ¬£¬Ò²Ã»ÓоÓÉÅú×¼µÄ¿¹²¡¶¾ÖÎÁÆÒªÁ죬£¬Í¨³£ÊÇʹÓ÷ÇçÞÌåÀ࿹Ñ×Ò©»òÀà¹Ì´¼£¬£¬ÎÔ´²ÐÝÏ¢£¬£¬ÒÔ¼°Ôö²¹Ë®·Ö¡£¡£ÖØÁ´¿¹ÌåµÄÖØÁ´µÄ¿É±äÇø³ÆÎªVHH£¬£¬Í¨¹ýÌåÍâÖØ×é±í´ïÖÆ±¸µÄVHH·Ö×ÓÖÊÁ¿½ö½öΪ15kDa£¬£¬ÊǹŰ忹ÌåµÄÊ®·ÖÖ®Ò»×óÓÒ£¬£¬ÊÇ¿¹ÔÁ¬ÏµÆ¬¶ÏµÄ¶þ·ÖÖ®Ò»×óÓÒ£¬£¬Òò´Ë±»³ÆÎªÄÉÃ׿¹Ì壨nanobody, Nb£©¡£¡£Óë¹Å°å¿¹ÌåÏà±È£¬£¬ÄÉÃ׿¹Ìå¿ÉÒÔʶÍâ¹Å°å¿¹Ìå²»¿Éʶ±ðµÄλµãÓÉÓÚÄÉÃ׿¹Ìå½ÏСµÄ³ß´çÒÔ¼°ÌØÊâµÄCDR3½á¹¹£¬£¬Ôö½øÁËÆäÓë¹Å°å¿¹ÌåËù²»¿ÉµÖ´ïµÄбíλµÄÏ໥×÷Ó㬣¬Òò´ËÄÉÃ׿¹Ìå¾ß±¸Á¬ÏµºÍÖк͹Ű忹ÌåÄÑÒÔÖÀÖеİеãµÄÄÜÁ¦£¬£¬ÊÊÓÃÓÚ²¡¶¾µÄ°ÐÏòÖÎÁÆ¡£¡£

ͼ1 ʵÑé·½°¸
¿ËÈÕ£¬£¬ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺ½¼Òº£½ÌÊÚ¡¢³ÂÔóÁ¼½ÌÊں͵ÚÒ»×÷ÕßµËÇ¿£¨ÔÚ¶Á²©Ê¿Éú£©µÈÔÚ¿¹²¡¶¾Ñо¿ÁìÓòÖ÷ҪѧÊõÆÚ¿¯Antiviral Research£¨IF=10.103£©ÉϽÒÏþÁËÌâΪ¡°Inhibition of Chikungunya virus early replication by intracellular nanoantibodies targeting nsP2 Epitope Rich Region¡±µÄÑо¿ÂÛÎÄ¡£¡£¸ÃÏîÑо¿ÓÉngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺ½¼Òº£½ÌÊÚÍŶÓÁìÏΣ¬£¬ÁªºÏÖÐÍâÍŶӣ¬£¬ÔڿƼ¼²¿ÖصãÑз¢ÍýÏëºÍ¹ã¶«Ê¡¶Ô½Ó¹ú¼ÒÖØ´óÏîĿ֧³ÖÏ£¬£¬´ÓÑòÍÕ×ÔÈ»ÊɾúÌå¿âÖÐɸѡ³öÁ˶à¸öÕë¶ÔCHIKV²¡¶¾nsP2¿¹ÔµÄÌØÒìÐÔÄÉÃ׿¹Ìå¡£¡£Ñо¿·¢Ã÷ÄÉÃ׿¹ÌåÄܹ»ÒÖÖÆ²¡¶¾ÔçÆÚ¸´ÖÆ¡£¡£¿¹ÌåµÄ»ñµÃ£¬£¬Îª½øÒ»²½Ñо¿CHIKV nsP2¹¦Ð§£¬£¬¿ª·¢ÖÎÁÆÒ©ÎïµÈµÓÚ¨ÁË»ù´¡¡£¡£
ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺ²©Ê¿ÉúµËǿΪÂÛÎĵÚÒ»×÷Õߣ¬£¬Â½¼Òº£º£ºÍ³ÂÔóÁ¼½ÌÊÚΪÂÛÎÄͨѶ×÷Õߣ¬£¬ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺΪ¸ÃÊÂÇéµÄµÚÒ»Íê³Éµ¥Î»¡£¡£ÉÏÊöÑо¿»ñµÃÁ˹ú¼ÒÖØµãÑз¢ÍýÏëÏîÄ¿(2018YFE0208000)¡¢¹ã¶«Ê¡ÖصãÁìÓòÑз¢ÍýÏëÏîÄ¿(2018B020241002)¡¢ÉîÛÚÊпƼ¼ÍýÏë (JSGG20220606142207017)¡¢¹ã¶«Ê¡Ò©Æ·¼àÊÓÖÎÀí¾Ö¿Æ¼¼Á¢ÒìÏîÄ¿£¨2022ZDZ12£©ºÍÖÐÑëÖ¸µ¼µØ·½¿Æ¼¼¿ªÕ¹×ʽð×ÔÓÉ̽Ë÷Àà»ù´¡Ñо¿ÏîÄ¿£¨2021Szvup171£©¡£¡£
ÂÛÎÄÁ´½Ó£º£ºhttps://doi.org/10.1016/j.antiviral.2022.105446